Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Antihypertensive

- PMLiVE

Almirall celebrates new offices in China to advance innovation in dermatology

The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners

- PMLiVE

Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

Petauri Evidence

- PMLiVE

AstraZeneca announces $2.5bn investment in China to boost R&D capabilities

The funds will go towards a new global research and development centre in Beijing’s BioPark

- PMLiVE

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Inizio

- PMLiVE

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Inizio

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Novo Nordisk growth takes a hit with China deal

Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products

- PMLiVE

Merck’s Keytruda gains two more approvals in Japan

New approvals in breast and colorectal cancer take the number of indication for the immunotherapy mega-blockbuster to 15 in Japan

- PMLiVE

AstraZeneca’s Forxiga approved in Japan for the treatment of CKD

Approval was based on positive data from the phase 3 trial for chronic kidney disease

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Inizio

- PMLiVE

Sinopharm’s COVID-19 vaccine scores approval in China

Vaccine found to be 79% effective in top-line results

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links